Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome


 

INTRODUCTION

Background: Since World War I, it has been known that patients with nonthoracic injuries, massive transfusion, sepsis, and other conditions may develop respiratory distress, diffuse lung infiltrates, and respiratory failure, sometimes after a delay of hours to days. After Ashbaugh described 12 such patients in 1967, the term adult respiratory distress syndrome (ARDS) was used to describe this condition. However, clear definition of the syndrome was needed to allow research into its pathogenesis and treatment. This was most recently refined in 1994 by the American-European Consensus Conference (AECC) on ARDS. The term acute respiratory distress syndrome rather than adult respiratory distress syndrome was used because the syndrome occurs in both adults and children.

ARDS was recognized as the most severe form of a diffuse alveolar injury, acute lung injury (ALI). Based on the AECC, ARDS is defined as an acute condition characterized by bilateral pulmonary infiltrates and severe hypoxemia in the absence of evidence for cardiogenic pulmonary edema. By these criteria, the severity of hypoxemia needed to make the diagnosis of ARDS is defined by the ratio of the patient's arterial oxygen partial pressure (PaO2) to the fractional concentration of oxygen in the inspired air (FIO2) ratio (PaO2 /FIO2). In ARDS, this ratio is less than 200. Cardiogenic pulmonary edema is excluded by a pulmonary capillary wedge pressure of less than 18 mm Hg in patients with a Swan-Ganz catheter in place or by clinical criteria consistent with a normal left atrial pressure. The AECC used the term ALI to define less severe respiratory impairment, as defined by a PaO2 /FIO2 ratio of 300 or less.

Pathophysiology: ARDS is associated with diffuse damage to the alveoli and lung capillary endothelium. The early phase is described as being exudative, whereas the later phase is fibroproliferative in character.

Early ARDS is characterized by an increase in the permeability of the alveolar-capillary barrier leading to an influx of fluid into the alveoli. The alveolar-capillary barrier is formed by the microvascular endothelium and the epithelial lining of the alveoli. Hence, a variety of insults resulting in damage either to the vascular endothelium or the alveolar epithelium could result in ARDS. The main site of injury may be focused on either the vascular endothelium (eg, sepsis) or the alveolar epithelium (eg, aspiration of gastric contents).

Injury to the endothelium results in increased capillary permeability and the influx of protein-rich fluid into the alveolar space. Injury to the alveolar lining cells also promotes pulmonary edema formation. There are 2 types of alveolar epithelial cells, type I, comprising 90% of the alveolar epithelium are injured easily. Damage to type I cells allows both increased entry of fluid into the alveoli and decreased clearance of fluid from the alveolar space. Type II cells are relatively more resistant to injury. However, type II cells have several important functions, including the production of surfactant, ion transport, and proliferation and differentiation into type l cells after cellular injury. Damage to type II cells results in decreased production of surfactant with resultant decreased compliance and alveolar collapse. Interference with the normal repair processes in the lung may lead to the development of fibrosis.

Neutrophils are thought to play an important role in the pathogenesis of ARDS. Evidence for this comes from studies of bronchoalveolar lavage (BAL) and lung biopsy specimens in early ARDS. Despite the apparent importance of neutrophils in ARDS, the syndrome may develop in profoundly neutropenic patients, and infusion of granulocyte colony-stimulating factor (GCSF) in patients with ventilator-associated pneumonia does not promote the development of ARDS. This and other evidence suggest to some that the neutrophils observed in ARDS may be reactive rather than having a causal role.

Cytokines, such as tumor necrosis factor (TNF), leukotrienes, macrophage inhibitory factor, and numerous others, along with platelet sequestration and activation, also are important in the development of ARDS. An imbalance of pro-inflammatory and anti-inflammatory cytokines is thought to occur after an inciting event, such as sepsis. Evidence from animal studies suggests that the development of ARDS may be promoted by the positive airway pressure delivered to the lung by mechanical ventilation. This is termed ventilator-associated lung injury.

ARDS is an inhomogeneous process. Relatively normal alveoli, more compliant than affected alveoli, may become overdistended by the delivered tidal volume resulting in barotrauma (pneumothorax and interstitial air). Alveoli already damaged by ARDS may suffer further injury by the shear forces exerted by the cycle of collapse at end expiration and reexpansion by positive pressure at the next inspiration; so called volutrauma. In addition to the mechanical effects on alveoli, these forces promote the secretion of pro-inflammatory cytokines with resultant worsening inflammation and pulmonary edema. The use of positive end-expiratory pressure (PEEP) to diminish alveolar collapse and the use of low tidal volumes and limited levels of inspiratory filling pressures appear to be beneficial in diminishing the observed ventilator-associated lung injury.

ARDS is associated with severe hypoxemia, and high inspired oxygen concentrations, therefore, are required to maintain adequate tissue oxygenation and life. Unfortunately, oxygen toxicity may promote further lung injury. Generally, oxygen concentrations greater than 65% for prolonged periods (days) result in diffuse alveolar damage, hyaline membrane formation, and, eventually, fibrosis.

ARDS is uniformly associated with pulmonary hypertension. Pulmonary artery vasoconstriction likely contributes to ventilation-perfusion mismatch and is one of the mechanisms of hypoxemia in ARDS. Normalization of pulmonary artery pressures occurs as the syndrome resolves. The development of progressive pulmonary hypertension is associated with a poor prognosis.

The acute phase of ARDS usually resolves completely. Less commonly, there is residual pulmonary fibrosis, in which the alveolar spaces are filled with mesenchymal cells and new blood vessels. This process seems to be facilitated by interleukin (IL)-1. Progression to fibrosis may be predicted early in the course by the finding of increased levels of procollagen peptide III (PCP-III) in the fluid obtained by BAL. This and the finding of fibrosis on biopsy correlate with an increased mortality rate.

Frequency:

Mortality/Morbidity: Until the 1990s, most studies reported a mortality rate for ARDS of 40-70%. However, 2 reports in the 1990s, one from a large county hospital in Seattle and one from the UK, suggested much lower mortality rates, in the 30-40% range. Possible explanations for the improved survival rates may be better understanding and treatment of sepsis, recent changes in the application of mechanical ventilation, and better overall supportive care of the critically ill patients.

Sex: For ARDS associated with sepsis and most other causes, there appears to be no differences in the incidence between males and females. However, in trauma patients only, there may be a slight preponderance of the disease in females.

Age: ARDS may occur at any age. The age distribution reflects the predilection of the underlying causes.

CLINICAL

History:

Physical:

Causes:

DIFFERENTIALS

Aspiration Pneumonia
Chemical Worker's Lung
Farmer's Lung
Hanta Virus Pulmonary Syndrome
Influenza
Legionellosis
Nosocomial Pneumonia
Opioid Abuse
Perioperative Pulmonary Management
Pneumococcal Infections
Pneumocystis Carinii Pneumonia
Pneumonia, Bacterial
Pneumonia, Viral
Pulmonary Edema, Cardiogenic
Pulmonary Edema, Neurogenic
Pulmonary Eosinophilia
Respiratory Failure
Sepsis, Bacterial
Septic Shock
Systemic Inflammatory Response Syndrome
Toxic Shock Syndrome
Toxicity, Cocaine
Toxicity, Salicylate
Transfusion Reactions
Tumor Lysis Syndrome


Other Problems to be Considered:

Pulmonary hemorrhage
Near drowning
Drug reaction
Noncardiogenic pulmonary edema
Hamman-Rich syndrome
Retinoic acid syndrome
Acute hypersensitivity pneumonitis
Transfusion-related acute lung injury (TRALI)
Acute eosinophilic pneumonia
Reperfusion injury
Leukemic infiltration
Pulmonary alveolar proteinosis
Fat embolism syndrome

WORKUP

Lab Studies:

Imaging Studies:

Other Tests:

Procedures:

Histologic Findings: The histologic changes in ARDS are those of diffuse alveolar damage. An exudative phase occurs in the first several days and is characterized by interstitial edema, alveolar hemorrhage and edema, alveolar collapse, pulmonary capillary congestion, and hyaline membrane formation. These histologic changes are nonspecific and do not provide information that would allow the pathologist to determine the cause of the ARDS. A biopsy performed after several days begins to show organization of the intra-alveolar exudate and repair, the proliferative phase of ARDS, which is characterized by the growth of type 2 pneumocytes in the alveolar walls and the appearance fibroblasts, myofibroblasts, and collagen deposition in the interstitium. The final phase of ARDS is fibrotic. Alveolar walls are thickened by connective tissue rather than edema or cellular infiltrate.

Staging: In the 1980s, Murray and coworkers developed a lung injury scoring system. This system was based on 4 parameters, as follows: severity of consolidation based upon CXR, severity of hypoxemia based upon the PaO2/FIO2 ratio, lung compliance, and level of PEEP required. This scoring system has proven helpful in clinical research in ARDS.

TREATMENT

Medical Care: There is no specific therapy for ARDS. Treatment of the underlying condition is essential, along with supportive care and appropriate ventilator and fluid management. As infection is often the underlying cause of ARDS, careful assessment of the patient for infected sites and institution of appropriate antibiotic therapy are key. In some instances, drainage of infected fluid collections or surgical debridement or resection of an infected site, such as ischemic bowel, may be essential because sepsis-associated ARDS does not resolve without such management. With the development of the NIH-sponsored ARDS Study Network, large well-controlled trials of ARDS therapies are underway. Thus far, the only treatment found to improve survival rates in such a study is a mechanical ventilation strategy employing low tidal volumes.

Surgical Care: The treatment of ARDS is medical. Surgical intervention may be required for some of the underlying causes of ARDS, as previously noted. In patients requiring prolonged mechanical ventilation, tracheostomy eventually is required.

Extracorporeal membrane oxygenation (ECMO) was shown in a large multicenter trial in the 1970's not to improve mortality in ARDS. Still, it remains a potential heroic measure in select cases.

Consultations: Treatment of patients with ARDS requires special expertise with mechanical ventilation and management of critical illness. Thus, a physician specializing in pulmonary medicine or critical care should be consulted.

Diet: Institution of nutritional support after 48-72 hours of mechanical ventilation usually is recommended. Unless contraindicated because of an acute abdomen, ileus, gastrointestinal bleeding, or other conditions, enteral nutrition via a feeding tube is preferable to intravenous hyperalimentation. A low carbohydrate, high fat enteral formula containing components that are anti-inflammatory and vasodilating (eicosapentaenoic acid and linoleic acid) with antioxidants has been shown to improve outcome in ARDS.

Activity: Patients with ARDS are at bedrest. Frequent position change and passive and, if possible, active range of motion activities of all muscle groups should be started immediately.

MEDICATION

No drug has proved beneficial in the prevention or management of ARDS. The early administration of corticosteroids in septic patients does not prevent the development of ARDS. Numerous pharmacologic therapies, including the use of inhaled synthetic surfactant, intravenous antibody to endotoxin, ketoconazole, and ibuprofen have been tried and are not effective. Small sepsis trials suggest a potential role for antibody to TNF and recombinant IL-1 receptor antagonist. Inhaled nitric oxide (NO), a potent pulmonary vasodilator looked promising in early trials, but in larger controlled trials did not change mortality rates in adults with ARDS. A potential role exists for corticosteroids in patients with late ARDS (fibroproliferative phase) because they decrease inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. This may be considered rescue therapy in selected patients, but widespread use is not recommended pending the results of an ARDS Network
trial now underway.

Drug Category: Corticosteroids -- Development of the late phase of ARDS may represent continued, uncontrolled inflammation requiring treatment with IV corticosteroids.
Drug Name
Methylprednisolone (Solu-Medrol) -- High-dose methylprednisolone has been used in several small trials of patients with ARDS who have persistent pulmonary infiltrates, fever, and high oxygen requirement despite resolution of pulmonary or extrapulmonary infection. Pulmonary infection is assessed with bronchoscopy and bilateral BAL and quantitative culture.
Adult Dose 2-3 mg/kg/d IV in divided doses
Pediatric Dose Not established
Contraindications Documented hypersensitivity; active tuberculosis; uncontrolled bacterial, viral, fungal, or tubercular infection
Interactions Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels of methylprednisolone; phenobarbital, phenytoin, and rifampin may decrease levels of methylprednisolone (adjust dose); monitor patients for hypokalemia when taking medication concurrently with diuretics
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Hyperglycemia, may mask fever and signs of acute abdomen

FOLLOW-UP

Further Inpatient Care:

Transfer:

Deterrence/Prevention:

Complications:

Prognosis:

MISCELLANEOUS

Medical/Legal Pitfalls:

Home page, Drug information's ,Regional anesthesia ,Index for  diseases ,Index for  diseases, Perioperative medicine, Search engine, Accreditation, Learn Arabic Warfare, Anesthesia LINKS, Orthopedic LINKS, Midline

Constructed by Dr N.A. Nematallah Consultant in perioperative medicine and intensive therapy, Al Razi Orthopedic Hospital , State of Kuwait, email : razianesth@freeservers.com